Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Open-Label, Randomized, Phase 3 Study

TKIs are the standard of care for patients with CML-CP, but some patients are resistant to or intolerant of available TKI therapies. Asciminib (ABL001) is a new TKI that targets the myristoyl pocket of BCR-ABL1 and functions as a potent and selective allosteric inhibitor, in contrast to currently available TKIs (eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib, radotinib) that target the BCR-ABL1 adenosine triphosphate (ATP) binding site. Asciminib has a resistance mutation profile that differs from those of ATP binding –site TKIs (Wylie AA, et al.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Michael Mauro, Carla Boquimpani, Yosuke Minami, Delphine R éa, Charisse Kemp, Shu-Fang Hsu Schmitz, Prashanth Gopalakrishna, Andreas Hochhaus Source Type: research